Leads Biolabs Doses First Patient in Phase I Part B Trial
Leads Biolabs says it dosed the first patient with systemic lupus erythematosus in the Phase I Part B trial of LBL-047.
Leads Biolabs says it dosed the first patient with systemic lupus erythematosus in the Phase I Part B trial of LBL-047.